Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement

Summary

The serum TXB₂ (sTXB₂) assay reflects the pharmacodynamics of platelet inhibition by low-dose aspirin. However, different studies reported variable sTXB₂ values. sTXB₂ assay requires whole blood incubation at 37 °C as a condition for optimal thrombin generation, arachidonic acid release and its metabolism by platelet cyclooxygenase-1 to form TXA₂. Access to 37 °C incubation may be variably delayed, and different methods to quantitate sTXB₂ may contribute to variable results between different Centers. We investigated whether delaying 37 °C incubation and/or analytical issues affect sTXB₂ concentrations, biasing the assessment of aspirin responsiveness. Sixty-eight samples from 54 volunteers, on- and off-aspirin, were incubated at 37 °C immediately after sampling (reference sample) or after 5, 10, 15, 20, 30 or 60 minutes at room temperature (RT); 8 samples remained at RT 60 minutes, without subsequent incubation; 314 sera were measured by enzyme immunoassay (EIA) and liquid chromatography-tandem mass-spectrometry (LC/MS-MS) methods. sTXB₂ concentrations decreased exponentially as a function of the delay before 37 °C incubation, ranging from 94 ± 11 % at 5 minutes to 23 ± 22 % of the reference sample after 60 minutes at RT. There was high agreement between EIA and LC/MS-MS. Moreover, we simulated the influence of a 15– or 30-minute delayed incubation on 300 sTXB2 measurements from previously-studied, aspirin-treated patients. Delayed incubation reduced the percentage of aspirin ‘non-responders’ by 22 % to 52 %, depending on the response threshold. In conclusion, a variable delay in the 37 °C incubation of blood samples may affect the assessment of platelet cyclooxygenase-1 inhibition by aspirin and confound the characterization of the determinants of aspirin responsiveness.

Keywords

Thromboxane B₂ - aspirin - cyclooxygenase-1 - liquid chromatographytandem mass spectrometry - enzyme immunoassay

• References

• 1 Patrono C, Ciabattoni G, Pinca E. et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327.
• 2 Patrono C, Ciabattoni G, Patrignani P. et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985; 72: 1177-1184.
• 3 Holinstat M, Boutaud O, Apopa PL. et al. Protease-activated receptor signaling in platelets activates cytosolic phospholipase A2alpha differently for cyclo-oxygenase-1 and 12-lipoxygenase catalysis. Arterioscler Thromb Vasc Biol 2011; 31: 435-442.
• 4 Rocca B, Secchiero P, Ciabattoni G. et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 2002; 99: 7634-7639.
• 5 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372.
• 6 Collaboration AT. Collaborative meta-analysis of randomised trials of antipla-telet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
• 7 Mehta SR, Bassand JP, Chrolavicius S. et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2009; 363: 930-942.
• 8 Patrignani P, Panara MR, Greco A. et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 271: 1705-1712.
• 9 FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433-442.
• 10 Product information. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/ 001241/WC500100494.pdf
• 11 Frelinger 3rd AL, Li Y, Linden MD. et al. Association of cyclooxygenase-1-de-pendent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation 2009; 120: 2586-2596.
• 12 Rocca B, Santilli F, Pitocco D. et al. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012; 10: 1220-1230.
• 13 Pascale S, Petrucci G, Dragani A. et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012; 119: 3595-3603.
• 14 Reny JL, Berdague P, Poncet A. et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 2012; 125: 3201-3210.
• 15 Brun C, Daali Y, Combescure C. et al. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets 2015; 1-7.
• 16 Patrono C, Ciabattoni G, Pugliese F. et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77: 590-594.
• 17 Zaccardi F, Rizzi A, Petrucci G. et al. In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus. Diabetes 2016; 65: 503-509.
• 18 Pradelles P, Grassi J, Maclouf J. Enzyme immunoassays of eicosanoids using acetylcholine esterase as label: an alternative to radioimmunoassay. Anal Chem 1985; 57: 1170-1173.
• 19 Santilli F, Rocca B, De Cristofaro R. et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol 2009; 53: 667-677.
• 20 Squellerio I, Porro B, Songia P. et al. Liquid chromatography-tandem mass spec-trometry for simultaneous measurement of thromboxane B2 and 12(S)-hydro-xyeicosatetraenoic acid in serum. J Pharm Biomed Anal 2014; 96: 256-262.
• 21 Lancellotti S, Dragani A, Ranalli P. et al. Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count. J Thromb Haemost 2015; 13: 1226-1237.
• 22 Bland JM, Altman DJ. Regression analysis. Lancet 1986; 01: 908-909.
• 23 Mortensen SB, Larsen SB, Grove EL. et al. Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 2010; 126: e318-322.
• 24 Fontana P, Berdague P, Castelli C. et al. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost 2010; 08: 2614-2623.
• 25 Maree AO, Curtin RJ, Dooley M. et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005; 46: 1258-1263.